Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

An open-label, multicenter, phase 1 study of ramucirumab (R) plus durvalumab (D) in patients (pts) with locally advanced and unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or hepatocellular carcinoma (HCC)

Date

09 Oct 2016

Session

Poster display

Presenters

Yung-Jue Bang

Citation

Annals of Oncology (2016) 27 (6): 359-378. 10.1093/annonc/mdw378

Authors

Y. Bang1, L.W. Goff2, H. Wasserstrom3, J. Yang3, G. Mi4, M. Karasarides5, M. Reck6

Author affiliations

  • 1 Department Of Internal Medicine, Seoul National University College of Medicine, - - Seoul/KR
  • 2 Hematology/oncology, Vanderbilt Ingram Cancer Center, Nashville/US
  • 3 Medical Oncology, Eli Lilly and Company, Bridgewater/US
  • 4 Medical Oncology/biostatistics, Eli Lilly and Company, Bridgewater/US
  • 5 Immunooncology, AstraZeneca, Wilmington/US
  • 6 Department Of Thoracic Oncology, Lungen Clinic Großhansdorf GmbH, Grosshansdorf/DE
More

Resources

Background

Hallmarks of tumor growth include angiogenesis and immunosuppression, and combining R (anti-vascular endothelial growth factor receptor 2 antibody) with D(anti-programmed death ligand-1 antibody) to target both processes demonstrates synergy in preclinical models. This global phase 1 trial (NCT02572687) will assess safety, toxicities, pharmacokinetics, immunogenicity, and preliminary efficacy of the combination in pts with locally advanced and unresectable or metastatic G/GEJ adenocarcinoma, NSCLC, or HCC.

Trial design

Key inclusion criteria include pts who have progressed on therapies, can provide a tumor biopsy sample, and have an ECOG PS of 0-1. Two combination dose/schedules will be evaluated in the Phase 1A/dose limiting toxicity (DLT) observation phase, following 6 + 3 dose de-escalation with a starting dose of R (10 mg/kg intravenous [IV]) and D (1125mg IV) Q3W for NSCLC and R (8 mg/kg IV) and D (750 mg IV) Q2W for G/GEJ and HCC (1 treatment cycle [21 days for the NSCLC cohort and 28 days for the Gastric-GEJ and HCC cohorts]). Phase 1A will include 18-54 pts. After the Phase 1A/DLT evaluation, each cohort will be expanded to approximately 20 pts who will receive study treatment until confirmed disease progression or unacceptable toxicity (Phase 1B). A final analysis will be performed 12 months after the last patient's first dose of study treatment. The primary objective is the assessment of the safety and tolerability of the combination of R + D, and the secondary objectives are pharmacokinetics (Phase 1A/1B) and preliminary efficacy and immunogenicity (Phase 1B). Interim analyses will occur after all pts within a cohort have completed (or discontinued from) approximately 24 weeks of treatment.

Clinical trial identification

NCT02572687

Legal entity responsible for the study

Eli Lilly and Company

Funding

Eli Lilly and Company

Disclosure

Y-J. Bang: Research fundings (through the institution) from Lilly, and consulting roles of Lilly.L.W. Goff: Advisory role for Celgene; research funding from Astellas Pharma, Pfizer, Onyx, Sun Pharma, Lilly, and Bristol-Myers Squibb. H. Wasserstrom, J. Yang, G. Mi: Employee of Eli Lilly and Company and holds equity in the company. M. Reck: Advisory role for Roche, Lilly, Bristol-Myers Squibb, AstraZeneca, Pfizer, Boehringer-Ingelheim, and Celgene. All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings